Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
sickle cell disease
Biotech
Inside Beam's 'big push' for in vivo gene editing
Riding a regulatory win for its base editing candidate, Beam is “putting all of our eggs” in the in vivo delivery basket, CEO John Evans said.
Angus Liu
Jan 21, 2026 7:52am
Pfizer pulls the plug on 11 programs
Nov 4, 2025 2:40pm
Pfizer's SCD drug fails ph. 3 study in latest blow to GBT legacy
Aug 18, 2025 7:31am
Novo inks IMMvention deal to orchestrate attack on sickle cell
Jan 22, 2025 9:41am
Vertex and Orna team up to develop new blood disorder treatments
Jan 7, 2025 7:00am
Beam hits hemoglobin goal in first base editing clinical data
Nov 5, 2024 9:00am
